Early VItrectomy in DENse Spontaneous Vitreous HEmorrhage

NCT ID: NCT04676256

Last Updated: 2024-02-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

126 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-02

Study Completion Date

2025-01-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the protocol is to compare the ocular outcomes after spontaneous vitreous hemorrhage treated with an early vitrectomy versus ultrasound monitoring with late vitrectomy.

The hypothesis is that an early vitrectomy could decrease the rate of retinal detachment occurring after a spontaneous vitreous hemorrhage.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of the protocol is to compare the ocular outcomes after spontaneous vitreous hemorrhage treated with an early vitrectomy versus ultrasound monitoring with late vitrectomy.

The hypothesis is that an early vitrectomy could decrease the rate of retinal detachment occurring after a spontaneous vitreous hemorrhage.

Scientific background Spontaneous vitreous hemorrhage may occur after spontaneous posterior vitreous detachment and causes retinal break and retinal detachment in about 70% and 40% of cases respectively. The fundus examination and ultrasound have limited sensitivity to detect retinal breaks in these cases. Some retrospective studies have highlighted the benefit of an early vitrectomy for decreasing the rate of visual loss due to retinal detachment in these cases. However, to date, there is no national or international consensus regarding the management of spontaneous vitreous hemorrhage and the timing of vitrectomy.

Study design Prospective randomized clinical trial Primary objective To compare the results of an early vitrectomy versus ultrasound and fundus observation in spontaneous vitreous hemorrhage.

Secondary objectives To evaluate the rate of retinal complications in spontaneous vitreous hemorrhage treated either with early or delayed vitrectomy.

To evaluate the rate of visual loss in spontaneous vitreous hemorrhage treated either with early or delayed vitrectomy.

Primary criteria Rate of retinal detachment in eyes with spontaneous vitreous hemorrhage treated with early vitrectomy versus ultrasound observation at 6-month follow-up Secondary criteria Rate of retinal breaks and vitreo-retinal proliferation in eyes with spontaneous vitreous hemorrhage treated with early vitrectomy versus ultrasound observation at 6-month follow-up Visual acuity and rate of eyes with a loss of 5 letters or more among eyes with spontaneous vitreous hemorrhage treated with early vitrectomy versus ultrasound observation at 6-month follow-up Participants Patients with a spontaneous vitreous hemorrhage secondary to posterior vitreous detachment, with a reduced visibility of the fundus Inclusion criteria

* Age \> or = 18 years old
* Spontaneous vitreous hemorrhage which is 1/ secondary to posterior vitreous detachment; 2/ acute: which duration is \< 15 days, 3/ dense: reduced visibility of the fundus

Exclusion criteria:

* Retinal detachment at the initial examination
* Any history of vascular retinal disease (diabetic retinopathy, retinal vein occlusion…)
* Any history of uveitis, age-related macular degeneration
* History of a recent ocular traumatism (\< 3 months)
* History of a recent retinal laser treatment (\< 3 months) or vitreo-retinal surgery (\< 3 months)
* Absence of consent Experimental group Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63) Active Comparator group Eyes with spontaneous vitreous hemorrhage only observed using fundus examination and B-ultrasound (n = 63) Study duration Inclusion: 12 months Participation: 6 months Total duration: 18 months

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spontaneous Vitreous Hemorrhage Retinal Break Retinal Detachment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Early Vitrectomy

Experimental arm will be treated with early vitrectomy early vitrectomy 7 days after vitreous hemorrhage diagnosis

Group Type EXPERIMENTAL

Early vitrectomy

Intervention Type PROCEDURE

Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63)

Comparator

Active comparator arm will have fundus and ultrasound observation. Late vitrectomy may be indicated after 3 months of follow-up if needed.

Late vitrectomy will be performed in case of persistant vitreous hemorrhage after 3 months of folllow-up

Group Type ACTIVE_COMPARATOR

Early vitrectomy

Intervention Type PROCEDURE

Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Early vitrectomy

Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> or = 18 years old
* Spontaneous vitreous hemorrhage which is :

1. secondary to posterior vitreous detachment;
2. acute: which duration is \< 15 days,
3. dense: reduced visibility of the fundus

Exclusion Criteria

* Retinal detachment at the initial examination
* Any history of vascular retinal disease (diabetic retinopathy, retinal vein occlusion…)
* Any history of uveitis, age-related macular degeneration
* History of a recent ocular traumatism (\< 3 months)
* History of a recent retinal laser treatment (\< 3 months) or vitreo-retinal surgery (\< 3 months)
* Absence of oral and written consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hopital Lariboisiere

Paris, Île-de-France Region, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Aude COUTURIER, MD, PhD

Role: CONTACT

+33149952474

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Aude Couturier, Dr

Role: primary

+33(0) 1.49.95.24.74

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IDRCB

Identifier Type: OTHER

Identifier Source: secondary_id

P170408J

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
NCT02858076 COMPLETED PHASE2/PHASE3